Form 4: Beyond Air CFO Granted 70,000 Stock Options

Beyond Air, Inc.'s Chief Financial Officer, Daniel J. Moorhead, received an inducement grant of 70,000 stock options with an exercise price of $0.79 per share.

Summary

• Daniel J. Moorhead, Chief Financial Officer of Beyond Air, Inc. (XAIR), was granted 70,000 stock options.
• The options were an inducement grant, issued on January 5, 2026.
• The exercise price for these options is $0.79 per share, which was the closing price of the company's common stock on January 2, 2026.
• The options have an expiration date of January 4, 2036.
• Vesting schedule: 25% of the options will vest on the one-year anniversary of the grant date (January 5, 2027), with the remaining options vesting annually in three equal installments thereafter.
• No portion of the stock option that is not exercisable at the time of the reporting person's termination of employment for any reason shall thereafter become exercisable.

Sentiment

Score: 6

Explanation: Slightly positive as it aligns management incentives with shareholder interests, though it introduces potential future dilution.

Positives

• The grant of stock options aligns the Chief Financial Officer's interests with those of shareholders, incentivizing long-term performance.
• The exercise price of $0.79 is at market value (closing price on January 2, 2026), indicating a performance-based incentive.

Negatives

• The issuance of 70,000 stock options represents potential future dilution for existing shareholders if exercised.

Risks

• The options are subject to a vesting schedule, and any unvested portion will be forfeited upon termination of employment for any reason.

Future Outlook

The stock options are subject to a multi-year vesting schedule, with 25% vesting on the one-year anniversary of the grant date and the remainder vesting in three equal annual installments thereafter, contingent on continued employment.

Management Comments

• Daniel J. Moorhead, Chief Financial Officer, received an inducement grant of 70,000 stock options.

Industry Context

Inducement grants of stock options are a common practice in the biotechnology and medical device industries, like Beyond Air, Inc., to attract and retain key executive talent. These grants are designed to align executive incentives with long-term shareholder value creation, particularly in companies focused on research, development, and commercialization where long-term commitment is crucial.

Comparison to Industry Standards

• Inducement grants, such as the 70,000 stock options granted to Beyond Air's CFO, are a standard component of executive compensation packages across various industries, including biotech.
• Companies like Moderna (MRNA) or BioNTech (BNTX) frequently utilize similar equity-based incentives to attract and retain top talent, especially in competitive sectors.
• The vesting schedule, with an initial one-year cliff and subsequent annual installments, is also a common structure designed to encourage long-term commitment and performance, comparable to practices seen at many publicly traded growth companies.

Corporate Governance

Related Party Transactions

• The grant of stock options to Daniel J. Moorhead, the Chief Financial Officer, constitutes a transaction with a related party (an executive officer).

Stakeholder Impact

• Shareholders: Potential for future dilution if options are exercised, but also benefit from incentivized management performance.
• Employees: The grant serves as an example of executive compensation, potentially influencing broader compensation strategies.

Next Steps

• The stock options will begin vesting on January 5, 2027, with subsequent annual vesting installments.

Key Dates

Recommendation

This Form 4 filing reports a routine executive compensation event (an inducement stock option grant) and does not contain information significant enough to warrant a change in investment recommendation. While it aligns management incentives, the potential dilution is minor in the context of overall company valuation, and the filing provides no new operational or financial performance data to alter a fundamental view of the stock.

Keywords

Beyond Air, XAIR, stock options, inducement grant, executive compensation, CFO, insider transaction, Form 4, equity compensation, Daniel Moorhead